Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases

NCT03463525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: [11C]osimertinib

Sponsor

AstraZeneca